Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schwegel, N; Strohhofer, C; Kolesnik, E; Oltean, S; Hüttmair, A; Pipp, C; Benedikt, M; Verheyen, N; Gollmer, J; Ablasser, K; Wallner, M; Santner, V; Tripolt, N; Pferschy, P; Zechner, P; Alber, H; Siller-Matula, JM; Kopp, K; Zirlik, A; Aziz, F; Sourij, H; von, Lewinski, D.
Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial.
Clin Res Cardiol. 2025; 114(5):629-639
Doi: 10.1007/s00392-024-02523-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kolesnik Ewald
- Schwegel Nora
- Co-Autor*innen der Med Uni Graz
- Ablasser Klemens
- Aziz Faisal
- Benedikt Martin
- Gollmer Johannes
- Pferschy Peter
- Santner Viktoria
- Sourij Harald
- Strohhofer Christoph
- Tripolt Norbert
- Verheyen Nicolas Dominik
- von Lewinski Dirk
- Wallner Markus
- Zechner Peter
- Zirlik Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Empagliflozin administered after acute myocardial infarction proofed to improve cardiometabolic parameters and biomarkers, but the impact on cardiac function is still largely unknown. The aim of this post-hoc echocardiographic sub-analysis of the EMMY trial was to provide in-depth echocardiographic analysis on the effects of empagliflozin versus placebo on standard and novel echocardiographic structural and functional parameters after acute myocardial infarction. METHODS: In this post-hoc analysis of the EMMY trial a subset of 313 patients (157 empagliflozin vs. 156 placebo) was enrolled for post-processing analysis of echocardiographic structural and functional parameters. On top of two-dimensional and Doppler parameters, myocardial deformation analyses were performed to assess ventricular and atrial strain values. RESULTS: Left ventricular volumes showed significant differences in favor of empagliflozin over the course of the trial (change in left ventricular end-diastolic volume median [interquartile range] 8 [-3;19]% versus 13 [0;29]%, p = 0.048; left ventricular end-systolic volume -3 [-15;12]% versus 4 [-12;18]%, p = 0.044). This effect persisted after adjusting for baseline values, age, and sex. Left ventricular systolic and diastolic function overall improved over the course of the trial and parameters for diastolic function showed a distinct trend between groups but did not meet statistical significance in this cohort. CONCLUSION: In this post-hoc analysis among patients with acute myocardial infarction, treatment with empagliflozin resulted in a significant beneficial effect on left ventricular end-diastolic and end-systolic volume, without significantly improving left ventricular or right ventricular functional parameters compared to placebo after 26 weeks. GOV REGISTRATION: NCT03087773.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Glucosides - therapeutic use, administration & dosage
- Benzhydryl Compounds - therapeutic use, administration & dosage
- Male - administration & dosage
- Female - administration & dosage
- Sodium-Glucose Transporter 2 Inhibitors - therapeutic use, administration & dosage
- Middle Aged - administration & dosage
- Ventricular Function, Left - drug effects, physiology
- Aged - administration & dosage
- Myocardial Infarction - drug therapy, physiopathology, diagnosis
- Treatment Outcome - administration & dosage
- Stroke Volume - drug effects
- Heart Ventricles - diagnostic imaging, physiopathology, drug effects
- Double-Blind Method - administration & dosage
- Echocardiography, Doppler - methods
- Find related publications in this database (Keywords)
- Myocardial infarction
- Echocardiography
- SGLT2 inhibitors
- Empagliflozin
- Heart failure
- Myocardial function